Business
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage
About this update from Genelux Corporation
[{"type":"text","content":"WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, today announced that it will ring the Nasdaq Stock Market (“Nasdaq”) opening bell on Wednesday, March 29, 2023 to commemorate its initial public offering, which occurred in January. “We are honored to be a Nasdaq-listed company, and our team is thrilled to be ringing the opening bell. This is an exciting time for Genelux as we take important steps to realize our goal of building a leading immunotherapy company. We appreciate the continued support of all our stakeholders as we take strides designed to unleash the power of our platform,” said Thomas Zindrick, President and Chief Executive Officer of Genelux. The Nasdaq opening bell ceremony will be broadcast live starting at 9:15 a.m. Eastern Time from the Nasdaq MarketSite Tower in New York City, New York. To view the broadcast, please visit: https://www.nasdaq.com/marketsite/bell-ringing-ceremony. Videos and photos during and following the ceremony will be shared on Nasdaq’s social media channels: Facebook, Instagram, and on Twitter. Genelux will also share the event across social media: LinkedIn, Facebook, and on Twitter @Genelux_Corp. About Genelux Corporation Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information please visit www.genelux.com. Forward-Looking Statements This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Ac...